MA33323B1 - Thérapie adjuvante de cancer - Google Patents

Thérapie adjuvante de cancer

Info

Publication number
MA33323B1
MA33323B1 MA34342A MA34342A MA33323B1 MA 33323 B1 MA33323 B1 MA 33323B1 MA 34342 A MA34342 A MA 34342A MA 34342 A MA34342 A MA 34342A MA 33323 B1 MA33323 B1 MA 33323B1
Authority
MA
Morocco
Prior art keywords
cancer
adjuvant therapy
adjuvant
compositions
provides methods
Prior art date
Application number
MA34342A
Other languages
Arabic (ar)
English (en)
Inventor
Gwendolyn Fyfe
Eric Hedrick
Robert D Mass
Norman Wolmark
Original Assignee
Genentech Inc
Nsabp Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Nsabp Foundation Inc filed Critical Genentech Inc
Publication of MA33323B1 publication Critical patent/MA33323B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Fertilizers (AREA)

Abstract

La présente invention porte sur des procédés et des compositions comprenant des anticorps anti-VEGF pour une utilisation dans une thérapie adjuvante de cancer.
MA34342A 2009-04-20 2010-04-20 Thérapie adjuvante de cancer MA33323B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17100809P 2009-04-20 2009-04-20
US17131809P 2009-04-21 2009-04-21
US18119509P 2009-05-26 2009-05-26
PCT/US2010/031740 WO2010123891A1 (fr) 2009-04-20 2010-04-20 Thérapie adjuvante de cancer

Publications (1)

Publication Number Publication Date
MA33323B1 true MA33323B1 (fr) 2012-06-01

Family

ID=42235124

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34342A MA33323B1 (fr) 2009-04-20 2010-04-20 Thérapie adjuvante de cancer

Country Status (19)

Country Link
US (1) US20100266589A1 (fr)
EP (1) EP2421558A1 (fr)
JP (1) JP2012524083A (fr)
KR (1) KR20120096401A (fr)
CN (1) CN102458467A (fr)
AR (1) AR076344A1 (fr)
AU (1) AU2010239368A1 (fr)
BR (1) BRPI1006438A2 (fr)
CA (1) CA2759030A1 (fr)
CL (1) CL2011002610A1 (fr)
CO (1) CO6450651A2 (fr)
CR (1) CR20110553A (fr)
IL (1) IL215764A0 (fr)
MA (1) MA33323B1 (fr)
MX (1) MX2011010955A (fr)
RU (1) RU2011147051A (fr)
SG (1) SG175289A1 (fr)
TW (1) TW201106969A (fr)
WO (1) WO2010123891A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA018260B1 (ru) 2006-09-29 2013-06-28 Онкомед Фармасьютикалз, Инк. Антитела к дельта-подобному лиганду 4 человека и их применение
ES2700450T3 (es) 2009-10-16 2019-02-15 Oncomed Pharm Inc Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
WO2011078301A1 (fr) 2009-12-25 2011-06-30 ファーマロジカルズ・リサーチ プライベート リミテッド Procédé de recherche et de dépistage d'une cible d'agent anticancéreux à l'aide d'un modèle animal non humain dans lequel a été transplantée une lignée de cellules cancéreuses établie sur nog
CN107898791A (zh) 2010-06-03 2018-04-13 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的应用
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
JP6230789B2 (ja) 2010-10-06 2017-11-15 中外製薬株式会社 癌幹細胞集団及びその作製方法
JP6077997B2 (ja) 2011-09-07 2017-02-08 中外製薬株式会社 癌幹細胞の分離
LT3485903T (lt) 2011-09-23 2023-02-27 Mereo Biopharma 5, Inc. Vegf/ dll4 surišantys agentai ir jų panaudojimas
US20140302511A1 (en) * 2011-10-28 2014-10-09 Pharmalogicals Research Pte. Ltd. Cancer stem cell-specific molecule
WO2013181452A1 (fr) * 2012-05-31 2013-12-05 Genentech, Inc. Procédés de traitement du cancer au moyen d'antagonistes liant l'axe pd-1 et d'antagonistes de vegf
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
SG11201500903XA (en) * 2012-08-07 2015-03-30 Genentech Inc Combination therapy for the treatment of glioblastoma
US9599620B2 (en) 2012-10-31 2017-03-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
SG11201503459SA (en) 2012-11-02 2015-06-29 Pharmacyclics Inc Tec family kinase inhibitor adjuvant therapy
US20140348821A1 (en) * 2013-05-24 2014-11-27 Nsabp Foundation, Inc. Defective Mismatch Repair and Benefit from Bevacizumab for Colon Cancer
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
WO2015143400A1 (fr) 2014-03-20 2015-09-24 Pharmacyclics, Inc. Mutations de phospholipase c gamma 2 et associées aux résistances
WO2016011052A1 (fr) 2014-07-14 2016-01-21 Genentech, Inc. Méthodes diagnostiques et compositions pour le traitement du glioblastome
WO2016070051A2 (fr) 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Thérapie combinée pour le traitement d'une maladie
WO2017042318A1 (fr) * 2015-09-10 2017-03-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptide de chémérine pour le traitement de la cachexie provoquée par le cancer
EP3353204B1 (fr) 2015-09-23 2023-10-18 Mereo BioPharma 5, Inc. Anticorps anti-vegf/dll4 bi-spécifique pour le traitement du cancer de l'ovaire résistant au platine

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582959B2 (en) * 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) * 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
WO1994004679A1 (fr) * 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
US5730977A (en) * 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
JP3957765B2 (ja) * 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド 抗ｖｅｇｆ抗体
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US6703020B1 (en) * 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
MXPA05012723A (es) * 2003-05-30 2006-02-08 Genentech Inc Tratamiento con anticuerpos anti-vgf.
US7758859B2 (en) * 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US20060009360A1 (en) * 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
TWI577695B (zh) * 2006-12-19 2017-04-11 建南德克公司 用於輔助及先導性輔助療法之血管內皮生長因子（ｖｅｇｆ）-特異性拮抗劑及早期腫瘤之治療
MX2009008132A (es) * 2007-02-01 2009-08-12 Genentech Inc Terapia de combinacion con inhibidores de angiogenesis.
TWI580694B (zh) * 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體

Also Published As

Publication number Publication date
US20100266589A1 (en) 2010-10-21
EP2421558A1 (fr) 2012-02-29
AU2010239368A1 (en) 2011-11-10
CA2759030A1 (fr) 2010-10-28
BRPI1006438A2 (pt) 2016-09-27
KR20120096401A (ko) 2012-08-30
WO2010123891A1 (fr) 2010-10-28
AR076344A1 (es) 2011-06-01
CO6450651A2 (es) 2012-05-31
RU2011147051A (ru) 2013-05-27
JP2012524083A (ja) 2012-10-11
TW201106969A (en) 2011-03-01
CN102458467A (zh) 2012-05-16
CL2011002610A1 (es) 2012-04-09
CR20110553A (es) 2012-01-23
SG175289A1 (en) 2011-11-28
MX2011010955A (es) 2012-04-02
IL215764A0 (en) 2012-01-31

Similar Documents

Publication Publication Date Title
MA33323B1 (fr) Thérapie adjuvante de cancer
MA32535B1 (fr) Compositions et procédés pour des anticorps ciblant une protéine du complément c5
MA32126B1 (fr) Anticorps et immunoconjugués anti-cd79b et leurs procédés d'utilisation
EA201390145A1 (ru) Конъюгаты, частицы, композиции и связанные с ними способы
MA33256B1 (fr) Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation
MX345909B (es) Anticuerpos anti-fgfr3 y métodos que los utilizan.
PH12013501339A1 (en) Anti-pcsk9 antibodies and methods of use
MY166776A (en) Humanised anti-ctla4 antibodies
EA201790664A1 (ru) Антитела против мезотелина и иммуноконъюгаты
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
ME03608B (fr) Anticorps monoclonaux contre la claudine-18 pour le traitement contre le cancer
MA34524B1 (fr) Anticorps pour le récepteur 3 du facteur de croissance épidermique (her3)
EA201171367A1 (ru) Винилиндазолильные соединения
EA201270553A1 (ru) Ингибиторы тирозинкиназы брутона
MA35009B1 (fr) Cristaux d'anticorps anti-sclérotine et formulations de ceux-ci
MX2010005080A (es) Metodos y composiciones para determinar la sensibilidad de linfoma de celula b al tratamiento con anticuerpos anti-cd40.
MX2012014080A (es) Usos y composiciones para el tratamiento de hidradenitis superativa (hs).
CU20120095A7 (es) Antagonistas de pcsk9
MX2013009362A (es) Anticuerpo contra el csf-1r.
UA99339C2 (ru) Антитело, которое специфично связывает человеческий tyrp1
MA35712B1 (fr) Anticorps anti-htra1 et leurs procédés d'utilisation
EP2111408A4 (fr) Compositions et procédés comprenant des microarn pour traiter une néoplasie
MX2013001473A (es) Anticuerpos contra il-18r1 y usos de los mismos.
MA34722B1 (fr) Méthodes et compositions pour l'immunothérapie de maladies neurales
GB0515353D0 (en) Food